Breckenridge Pharmaceutical, Inc: Drug Recall

Recall #D-0482-2024 · 04/29/2024

Class II: Risk

Recall Details

Recall Number: D-0482-2024
Classification: Class II
Product Type: Drug
Recalling Firm: Breckenridge Pharmaceutical, Inc
Status: Ongoing
Date Initiated: 04/29/2024
Location: Berlin, CT, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 281,554/90 & 1000 count bottles

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Product Description

Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, (a) 90-count bottles (NDC 51991-747-90), (b) 1000-count bottles (NDC 51991-747-10), Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

Distribution Pattern

US Nationwide.

Other Recalls by Breckenridge Pharmaceutical, Inc

Class II: Risk 11/24/2025

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Class II: Risk 11/24/2025

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Class II: Risk 10/09/2025

CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
Class II: Risk 08/08/2025

CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
Class II: Risk 07/25/2025

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

View all recalls by Breckenridge Pharmaceutical, Inc →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.